




INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 5 : A61K 31/41, 31/28 // C07D 293/12		A1	(11) International Publication Number: WO 92/02221
			(43) International Publication Date: 20 February 1992 (20.02.92)
(21) International Application Number: PCT/EP91/01438		(74) Agents: STERNAGEL, Hans-Günther et al.; Sander Aue 30, D-5060 Bergisch Gladbach 2 (DE).	
(22) International Filing Date: 31 July 1991 (31.07.91)			
(30) Priority data: P 40 24 885.2 6 August 1990 (06.08.90) DE		(81) Designated States: AT (European patent), BE (European patent), CA, CH (European patent), DE (European patent), DK (European patent), ES (European patent), FR (European patent), GB (European patent), GR (European patent), IT (European patent), JP, LU (European patent), NL (European patent), SE (European patent), US.	
(71) Applicant (for all designated States except US): RHONE-POULENC RORER GMBH [DE/DE]; Nattermannallee 1, D-5000 Cologne 30 (DE).		Published With international search report.	
(72) Inventors; and (75) Inventors/Applicants (for US only) : BALDEW, Glenn, S. [NL/NL]; Steijnlaan 114, NL-2571 RH Den Haag (NL). VERMEULEN, N., P., E. [NL/NL]; Akkerhoornbloem 21, NL-2317 KR Leiden (NL). DE GOEIJ, J., J., M. [NL/NL]; Prof. Albrechtsln. 1, NL-2215 Voorhout (NL). McVIE, J., G. [GB/GB]; 18th Trinity Gey, Edinburgh EHS 3EE (GB). LOS, G. [NL/NL]; St. Jansstraat 21, NL-1433 HT Kudelstaart (NL). VAN DER VALK, M., A. [NL/NL]; Van der Veldelaan 37, NL-1861 PA Alkmaar (NL).			

(54) Title: USE OF 2-PHENYL-1,2-BENZISOSELENAZOL-3(2H)-ONE



(57) Abstract

2-Phenyl-1,2-benzisoselenazol-3(2H)-one(Ebselen) is capable of reducing the cisplatin-induced nephrotoxicity and neurotoxicity during cytostatic treatment.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	ES	Spain	MG	Madagascar
AU	Australia	FI	Finland	ML	Mali
BB	Barbados	FR	France	MN	Mongolia
BE	Belgium	GA	Gabon	MR	Mauritania
BF	Burkina Faso	GB	United Kingdom	MW	Malawi
BG	Bulgaria	GN	Guinea	NL	Netherlands
BJ	Benin	GR	Greece	NO	Norway
BR	Brazil	HU	Hungary	PL	Poland
CA	Canada	IT	Italy	RO	Romania
CF	Central African Republic	JP	Japan	SD	Sudan
CG	Congo	KP	Democratic People's Republic of Korea	SE	Sweden
CH	Switzerland	KR	Republic of Korea	SN	Senegal
CI	Côte d'Ivoire	LI	Liechtenstein	SU ⁺	Soviet Union
CM	Cameroon	LK	Sri Lanka	TD	Chad
CS	Czechoslovakia	LU	Luxembourg	TC	Togo
DE	Germany	MC	Monaco	US	United States of America
DK	Denmark				

⁺ It is not yet known for which States of the former Soviet Union any designation of the Soviet Union has effect.

Title: Use of 2-phenyl-1,2-benzisoselenazol-3(2H)-one

Description

The invention concerns a new use for 2-phenyl-1,2-benzisoselenazol-3(2H)-one (Ebselen) for the treatment and prophylaxis of the side effects that can be caused by medicinal administration of cisplatin and of pharmaceutical preparations containing this drug and the application of Ebselen for the manufacture of medicinal preparations for the treatment of the side effects that can occur on medicinal treatment with cisplatin, or for prophylaxis against them.

2-Phenyl-1,2-benzisoselenazol-3(2H)-one is a known compound that can be used for the treatment of rheumatism (DE-OS 30 27 073) or for the treatment of oxidative stress (DE-OS 36 16 923). The compound can be prepared, for example, by the reaction of 2-methylseleno-N-phenyl-benzamide with phosphorus pentachloride followed by hydrolysis according to the method of M. Renson and R. Weber (Bulletin de la Soc. Chim. de France 1976 (7/8), p. 1124-1126).

Cisplatin is a cytostatic often used in cancer therapy for the treatment of many different types of tumor. The medicament is highly effective for the treatment of various solid tumors, such as cancer of the testes, ovaries, bladder, head and neck and "non-small cell" lung cancer.

However, its clinical application is frequently exceedingly difficult, since its mechanism of action does not only affect pathological cells but healthy cells as well, thus causing damage to the body.

These side effects most frequently manifest themselves in the form of a (gradual) renal intoxication, intoxication of the gastrointestinal tract, of the peripheral nerves and of the bone marrow (deposition of platinum).

The occurrence of nephrotoxicity and/or neurotoxicity is most frequent.

The neurotoxicity is a further serious and clinically relevant side effect. On chronic administration it manifests itself in the form of primary sensory neuropathy, retrobulbar neuritis and neurosensory deafness.

There have been many attempts to compensate for or minimize these negative side effects of cisplatin administration.

Thus, various derivatives of cisplatin have been found to produce fewer undesirable side effects, but the actual cytotoxic effect of the administered substance is considerably reduced in parallel.

In the past some substances, such as sodium thiosulfate (L.E. Pfeifle et al., J. Clin. Oncol. 3 (1987), p. 237-244) and diethyl dithiocarbamate (D.L. Bodenner et al., Cancer Res. 46 (1986), p. 2751-2755), have been tested for ability to protect healthy cells from the effects of cisplatin. These substances do provide a certain degree of protection against the nephrotoxic and/or neurotoxic effects of cisplatin, but their clinical application is limited by the fact that thiosulfate reduces the pharmacodynamic efficacy of cisplatin; this phenomenon does not occur with diethyl dithiocarbamate, but the substance is very toxic.

It is already known that simple selenium compounds - sodium diselenite for instance - are able to reduce cisplatin-induced nephrotoxicity in mice without reducing the tumor-inhibiting activity of cisplatin (J.P. Berry et al., Cancer Res. 44 (1984) 2864-2868 and Baldew et al., Cancer Res. 49 (1989) 3020-3023, amongst others). However, the high potential toxicity of selenium prohibits human clinical applications.

The object of the present invention is to provide a drug that inhibits or obviates the side effects of medicinal administration of cisplatin itself.

Surprisingly it was found that this purpose can be achieved by administering cisplatin together with 2-phenyl-1,2-benzisoselenazol-3(2H)-one (Ebselen).

The object of the invention is achieved by the use of 2-phenyl-1,2-benzisoselenazol-3(2H)-one for the manufacture of medicaments for the treatment and prophylaxis of the side-effects occurring on the medicinal administration of cisplatin.

The administration of cisplatin with Ebselen leads to an appreciable diminution in the side effects produced by cisplatin; a practically complete inhibition was observed in the case of the nephrotoxicity and/or neurotoxicity induced by cisplatin.

Ebselen can be administered simultaneously with cisplatin, but administration over a period extending from 1 hour before and after the administration of cisplatin does not diminish the effect of Ebselen.

In a preferred embodiment a combination of cisplatin with Ebselen is used for the manufacture of medicaments for the treatment of neoplastic diseases and prophylaxis of the side-effects occurring on the medicinal administration of Cisplatin, comprising of 10 mg to 100 mg Cisplatin and 10 mg to 2000 mg Ebselen. Preferably the combination is in the form of a medical kit of the two active ingredients comprising collection or package containing the two agents in separate but adjacent form for the use according to the present invention.

Since, in contrast to the previously known and applied selenium compounds, Ebselen is low in toxicity ($LD_{50} > 1000$ mg/kg body weight in acute investigations in mice and rats) and the maximum doses to be administered lie greatly below this value, administration to patients can be regarded as being without danger.

Cisplatin-induced nephrotoxicity

The influence of Ebselen on cisplatin-induced toxic effects could be proven in two different methodological approaches:

- 1) in an in-vitro investigation in a cell line which expresses many of the characteristics of proximal tubular cells
- 2) in-vivo in mice subject to a tumor-inducing treatment.

The aim of the investigations was to get information on the influence of Ebselen on the cisplatin side-effects as well as on the antitumor potency of the drug.

- 1) Influence on in-vitro toxicity of cisplatin in LLC-PK₁ cells

LLC-PK₁ are porcine kidney cells which express many characteristics of proximal tubule epithelium. The LLC-PK₁ cell has been used to study the nephrotoxicity of cisplatin. In this cell line the LDH-leakage can be used as criterium for cell toxicity.

Material and Methods

LLC-PK₁ cells were obtained from Flow Laboratories, Zwanenburg, The Netherlands and maintained by serial passages in 75-cm² plastic culture flasks in an atmosphere of 5 % CO₂ -95% air at 37 °C. The complete medium consisted of E 199 medium (Flow laboratories), supplemented with 2 mM L-Glutamine and 5 % Fetal Calf Serum. Cells were seeded in 24 well culture dishes (0.2 cm²/well) and allowed to grow to confluence (2.4 x 10⁵ cell/cm²) over 8 days in serum containing 5 % fetal calf serum. The cells were then maintained in serum-free medium for 2 days before drug treatment. Only monolayers in which dome formation occurred were used for the experiments.

Cisplatin was dissolved in a sterile salt solution (114 mM NaCl, 5.4 mM KCl, 0.8mM MgCl₂, 1.2 mM CaCl₂, 0.8 mM Na₂HPO₄, 0.2 mM NaH₂PO₄, 16 mM NaHCO₃, 5.5 mM glucose), saturated with 5% CO₂ -95% air at 37°C (pH 7.4). Ebselen was dissolved in 2% dimethylsulfoxide in the sterile salt solution.

Monolayers of LLC-PK₁ were lysed with trypsin and cell viability was assessed by measuring LDH activity, according to the method of Stevens et al. (J. Biol. Chem., (1986) 261: 3325-3332), and by measuring the amount of protein remaining attached to the culture plate with bovine serum

albumine as standard, according to the method of Lowry et al. (J. Biol. Chem., (1951) 193: 265-275).

Monolayers of LLC-PK₁ cells were washed twice with physiological saline and then exposed to cisplatin or ebselen for 60 min. After incubation, the monolayers were washed 3 times with physiological saline to remove residual drug. Subsequently, the cells were grown in medium containing 5% fetal calf serum. Cell viability was assessed at different timepoints. In control experiments, monolayers were exposed to the vehicle in stead of drugs.

The influence of ebselen on the cytotoxicity of cisplatin in LLC-PK₁ cells was estimated by washing monolayers of LLC-PK₁ cells twice with physiological saline and incubation with ebselen for 60 min. Subsequently, monolayers were washed 3 times with physiological saline and incubated with cisplatin as described above. In control experiments, ebselen was replaced by the vehicle.

Results

Cytotoxicity of cisplatin in LLC-PK₁ cells.

The influence of cisplatin at several concentrations on the viability of LLC-PK₁ cells is shown in Fig. 1.

Fig 1.

Cytotoxicity of cisplatin in LLC-PK₁ cells. Quiescent cells were exposed to cisplatin for 1 h, washed and then incubated in fresh medium until assayed for viability by measuring LDH-leakage (A) and the amount of protein remaining attached to the culture plate (B). Data represent one typical example out of three independent experiments. SD < 6%.

Measurements of LDH and of the amount of protein remaining attached to the culture plate, yielded similar results. Exposure of the quiescent cells to a cisplatin concentration of 0.4 mM during 1 h, followed by maintenance of the cells in drug free medium, caused a decrease in cell viability, which was first observed 24 h after termination of the incubation with cisplatin. Cell viability was further reduced to 21% in the next 48 h. Under these conditions, a cisplatin concentration of 0.1 mM did not significantly reduce the cell viability, measured up to 72 h after exposure.

Exposure of the LLC-PK₁ cells to Ebselen, 5-15 μ M, for 1 h did not alter their viability as measured by the leakage of intracellular LDH in the medium and by the amount of protein remaining attached to the culture plate, up till 72 h after exposure.

The influence of Ebselen on the cytotoxicity of cisplatin in LLC-PK₁ cells.

The results presented in Fig. 2 demonstrate that pre-incubation of the LLC-PK₁ cells with Ebselen, 5-15 μ M for 1 h, protected the cells from a decrease in viability induced by exposure of the cells to 0.2 or 0.4 mM cisplatin.

Fig. 2

The influence of ebselen on the cytotoxicity of cisplatin in LLC-PK₁. Quiescent cells were exposed to ebselen for 1 h, washed exposed to cisplatin for 1 h, washed and then incubated in fresh medium until assayed (t = 72 h) for viability by measuring LDH-leakage (A) and the amount of protein remaining attached to the culture plate (B). Data represent one typical example out of three independent experiments. SD < 6%.

The protective effect of Ebselen was concentration-dependent: the highest protection was obtained at an ebselen concentration of 15 μ M.

Pre-incubation of ebselen could not protect the cells against the decrease in viability caused by exposure to a cisplatin concentration of 0.8 mM for 1 h.

The protective effect of Ebselen as function of the time after exposure to cisplatin is plotted in Fig. 3.

Fig 3.

Time course of the protective effect of ebselen on the cytotoxicity of cisplatin in LLC-PK₁ cells. Quiescent cells were exposed to 10 uM ebselen for 1 h, washed, exposed to 0.4 mM cisplatin for 1 h, washed and then incubated in fresh medium until assayed for viability by measuring LDH-leakage (A) and the amount of protein remaining attached to the culture plate (B). Data represent one typical example out of three independent experiments. SD < 6%.

As shown, the viability of the cells, measured after exposure to 0.4 mM cisplatin for 1 h, was during the whole period (up till 72 h exposure) significantly higher in cells which were pre-exposed to 10 uM Ebselen for 1 h.

2) Influence on in-vivo toxicity of cisplatin in mice

Tumors. MPC 11 tumor cells were obtained from the institute of Pathology, University of Utrecht, The Netherlands. The MPC 11 tumor originated as a plasmacytoma, and was originally obtained from Dr. D. Catty, Birmingham, United Kingdom. The tumor cells were maintained by weekly passages in BALB/c mice. Freshly harvested ascitic cells were used in the experiments. Cells were counted with a hemocytometer. Transplantable Prima mammary tumor cells were obtained from the Radiobiological Institute TNO, Rijswijk, The Netherlands. The Prima tumor originated as a mammary carcinoma, induced by forced breeding in BALB/c mice bearing murine mammary tumor virus. The Prima tumor cell-line was cultured in vitro in standard Dulbecco's modification of Minimal Essential Medium (Gibco, Paisley, United Kingdom), supplemented with L-glutamine (500 mg/l), 2-mercapto-ethanol (60 μ mol/l) and 10% fetal calf serum (Flow Laboratories, Zwanenburg, The Netherlands).

Laboratory Animals. Female BALB/c mice were obtained from the Central Institute for the Breeding of Laboratory Animals/Harlan Sprague-Dawley (CPB/HSD), Zeist, The

Netherlands. The mice were 8 weeks of age and weighed 18-20 g at the start of the experiments. All animals were provided with standard laboratory food (SRMA chow, Hope Farms, Woerden, The Netherlands) and water ad libitum.

Treatment. Animals were divided at random into groups of 8. Cisplatin was administered in 1.0 ml physiological saline. Ebselen was dissolved in a mixture of dimethylsulfoxide/polyethyleneglycol/physiological saline (1/4/20) and administered i.p. in a volume of 0.6 ml.

Kidney Function. The influence of Ebselen on cisplatin-induced nephrotoxicity was studied by injection of ebselen i.p. 1 h prior to or 1 h after cisplatin administration. Control groups were treated with Ebselen or the vehicle. Blood samples were obtained from the retroorbital venous plexus in the mice. Serum creatinine and BUN were measured daily in pilot studies (data not shown) and in more extensive studies at the time of maximally observed toxicity : Day 4.

Liver Function. Serum glutamic pyruvate transaminase (sGPT) and SGOT were determined on Days 1 and 4 after treatment with cisplatin or ebselen and cisplatin. Control groups were treated with ebselen or the vehicle.

Histology. Mice were sacrificed four days after treatment with cisplatin alone or Ebselen and cisplatin. Control groups were treated with Ebselen alone or the vehicle. Kidneys and livers were removed and processed for light microscopy. Sections of 6 μ m thickness were cut and stained in hematoxylin : eosin. All slides were examined without prior knowledge of the treatment given to the animal from which the specimen under investigation was taken.

Evaluation of Antitumor Activity. The influence of ebselen on the antitumor activity of cisplatin against an ascitic tumor was examined in BALB/c mice, i.p. inoculated with 10^6 MPC tumor cells on Day 0. After 24 h, the mice were treated with a single i.p. dose of cisplatin. The influence of ebselen was assessed by injecting ebselen i.p. 1 h prior to cisplatin. Control groups were treated with ebselen or the vehicle. Mice were examined daily for occurrence of tumors. The experiments were terminated on Day 42 and median survival times (MSTs) were calculated.

BALB/c mice, inoculated with 0.5×10^6 Prima tumor cells s.c. in the left thigh (Day 0), were used to investigate the effect of Ebselen on the antitumor activity of cisplatin against solid tumors. One group of mice was treated with a

single i.p. dose of cisplatin 24 h after inoculation of tumor cells. Another group was treated with a single i.p. injection of ebselen 1 h before cisplatin. Control groups were treated with ebselen or the vehicle. The occurrence of tumors was examined daily by palpation. The experiments were terminated on Day 15 when the tumors were excised and weighed.

Statistics. Student's test, unpaired, was used to evaluate the significance of differences between experimental groups. The level of significance was set at $P < 0.05$.

Results

Toxicity of Ebselen. It could be demonstrated that ebselen itself did not cause functional liver- or kidney-damage in BALB/c mice.

The influence of Ebselen on nephrotoxicity of cisplatin. The data in Table 1 demonstrate a dose-dependent protective effect of ebselen against cisplatin-induced nephrotoxicity in mice. Maximal protection was obtained with an ebselen dose of 10.0 mg/kg. The results, summarized in Table 2, demonstrate a protective effect of ebselen against nephrotoxicity induced by various cisplatin doses in mice.

Administration of cisplatin in a dose range of 11.5 to 19.0 mg/kg increased levels of BUN and serum creatinine at Day 4 posttreatment. Administration of Ebselen 1 h before cisplatin prevented the increase in levels of BUN and serum creatinine at all cisplatin doses tested with exception of the highest dose. When ebselen was administered 1 h after cisplatin, a protective effect against cisplatin-induced elevations of the levels of BUN and serum creatinine was also observed, but less marked.

The protective effect of Ebselen against cisplatin-induced kidney damage, as observed by BUN and creatinine levels, was confirmed by histology. The tubules of the kidneys of mice treated with Ebselen, 10 mg/kg and 1 h thereafter with cisplatin showed considerably less degeneration and less cell loss of the tubular epithelium at Day 4 posttreatment than those of mice treated with cisplatin alone.

Retroperitoneal ganglionic-tissue attached to the kidneys was also examined histologically. Damage to retroperitoneal ganglionic cells was more pronounced in mice treated with cisplatin alone than in mice treated with cisplatin and ebselen administered 1 h before cisplatin. These observations suggest that ebselen might also be able to provide protection against cisplatin-induced neurotoxicity.

The influence of Ebselen on the antitumor activity of cisplatin. MPC 11 plasmacytoma. The antitumor activities of various cisplatin/ebselen combinations in BALB/c mice, inoculated with MPC 11 tumor cells, are shown in Table 3. Ebselen did not reduce the antitumor activity of cisplatin. Down to cisplatin doses as low as 6.5 mg/kg, no significant differences were observed in median survival time (MST) of mice treated with cisplatin compared with those of mice treated with the corresponding cisplatin dose plus ebselen. Treatment with ebselen alone resulted in a MST identical to that of the control group treated with the vehicle alone.

The data in Table 3 also show that ebselen protects BALB/c mice against cisplatin nephrotoxicity without reducing the efficacy of the drug against the MPC 11 tumor. The mean BUN level of mice inoculated with MPC 11 tumor cells and treated with cisplatin, 13.0 mg/kg, was 162 ± 56 mg/100 ml on Day 5. Four animals of this group (n=8) were dead on Day 7. The surviving animals did not develop tumors (MST > 42 days). MST of mice inoculated with 10 MPC 11 cells on Day 0 was 16 days. All mice (n=8) treated with ebselen, 10 mg/kg, and cisplatin 13.0 mg/kg, survived (MST > 48 days). These mice did not develop tumors. The mean BUN level of these mice was 29 ± 10 mg/100 ml on Day 5, which is much lower than that of the group treated with cisplatin alone.

Prima tumor. Cisplatin in doses of 9.0 and 11.5 mg/kg was effective against the Prima mammary tumor in BALB/c mice (Table 4). Ebselen (10 mg/kg) was not effective against the Prima tumor and did not reduce the antitumor activity of cisplatin.

The data in Table 4 also show that ebselen reduced the nephrotoxicity but not the antitumor activity of cisplatin in Prima tumor bearing mice. Mice (n=8) treated with cisplatin alone, 13.0 mg/kg, showed highly elevated BUN-levels (mean : 148 ± 85 mg/100 ml) on Day 5, but the animals survived. None of the mice of this group had tumors as assessed by palpation on Day 7. On the other hand, none of the mice treated with ebselen and cisplatin showed kidney damage. All mice survived and none of them had tumors. Neither BUN levels on Day 5 nor mean tumor weight on Day 15 of mice treated with ebselen alone were significantly different from those of the control group, treated with the vehicle alone.

Table 1. The influence of various ebselen doses on the nephrotoxicity of cisplatin in BALB/c mice

Cisplatin (mg/kg)	Ebselen ^a (mg/kg)	BUN (mg/100 ml)	Creatinine (mg/100 ml)
0 ^b	0	22 ± 2 ^c	0.54 ± 0.03
0	10.0	21 ± 3	0.53 ± 0.03
14.5	0	184 ± 33	5.9 ± 0.6
14.5	2.5	154 ± 59	5.4 ± 0.7
14.5	5.0	105 ± 20 ^d	3.0 ± 1.0 ^d
14.5	7.5	72 ± 17 ^d	1.7 ± 0.4 ^d
14.5	10.0	37 ± 10 ^d	0.73 ± 0.07 ^d
14.5	12.5	44 ± 18 ^d	0.69 ± 0.08 ^d

^a Ebselen was administered i.p. 1 h before cisplatin

^b Control animals were injected with the vehicle

^c Mean ± (n=8)

^d p<0.05 compared to the groups, treated with cisplatin alone

SUBSTITUTE SHEET

Table 2. The influence of ebselen on the nephrotoxicity of various cisplatin doses in BALB/c mice

Cisplatin (mg/kg)	Ebselen (mg/kg)	BUN (mg/100 ml)	Creatinine (mg/100 ml)
0 ^a	0	20 ± 2 ^b	0.53 ± 0.03 ^b
0	10.0 ^c	19 ± 3	0.53 ± 0.02
11.5	0	70 ± 42	1.6 ± 0.6
11.5	10.0 ^c	22 ± 5 ^d	0.54 ± 0.04 ^d
13.0	0	130 ± 38	4.5 ± 1.0
13.0	10.0 ^c	40 ± 27 ^d	0.83 ± 0.05 ^d
13.0	10.0 ^e	67 ± 23 ^d	1.5 ± 0.3 ^d
14.5	0	175 ± 52	5.8 ± 0.7
14.5	10.0 ^c	57 ± 16 ^d	1.2 ± 0.3 ^d
14.5	10.0 ^e	102 ± 22 ^d	2.8 ± 0.3 ^d
16.0	0	232 ± 40	6.4 ± 1.0
16.0	10.0 ^c	108 ± 55 ^d	3.2 ± 0.6 ^d
19.0	0	275 ± 26	6.9 ± 0.2
19.0	10.0 ^c	133 ± 70 ^d	4.5 ± 0.8 ^d

^a Control animals were injected with the vehicle

^b Mean ± SD (n=8)

^c Ebselen was given before cisplatin

^d p<0.05 compared to the groups, treated with cisplatin alone

^e Ebselen was given 1 h after cisplatin

SUBSTITUTE SHEET

Table 3. The influence of ebselen on the nephrotoxicity and antitumor activity of cisplatin in BALB/c mice inoculated with MPC 11 tumor cells (n=8)

Cisplatin (mg/kg)	Ebselen ^a (mg/kg)	BUN (mg/100 ml)	Survival Day 7 (%)	Incidence of tumors		T/C ^b %
				Day 7 (%)	MST (days)	
0	0	22 ± 1 ^c	100	100	16 ± 3	100
0	10.0	20 ± 2	100	100	17 ± 2	106
4.0	0	22 ± 2	100	100	24 ± 4	150
4.0	10.0	20 ± 2	100	100	23 ± 5	144
6.5	0	23 ± 3	100	100	29 ± 4	181
6.5	10.0	22 ± 2	100	100	30 ± 2	188
9.0	0	21 ± 2	100	0	>30	>300
9.0	10.0	23 ± 2	100	0	>48	>300
11.5	0	86 ± 32	87.5 ^d	0	>48	>300
11.5	10.0	24 ± 3 ^e	100	0	>48	>300
13.0	0	162 ± 56	50 ^d	0	>48	>300
13.0	10.0	29 ± 10 ^e	100	0	>48	>300
14.5	0	204 ± 32	0	0	>48	>300
14.5	10.0	79 ± 46 ^e	75 ^d	0	>48	>300

^a Ebselen was given 1 h before cisplatin

^b T/C=MST treated/ MST control

^c Mean ± SD

^d Mice alive at Day 7 did not develop tumors as judged by daily examination and by autopsy on Day 48. Mice, dead on Day 7 were presumed to have died from cisplatin toxicity

^e p<0.05 compared to the groups treated with cisplatin alone

SUBSTITUTE SHEET

Table 4. The influence of ebselen on the nephrotoxicity and antitumor activity of cisplatin in BALB/c mice inoculated with Prima breast tumor cells (n=8).

Cisplatin (mg/kg)	Ebselen ^a (mg/kg)	BUN Day 5 (mg/100 ml)	Survival Day 8 (%)	Incidence of tumors Day 8 ^c (%)	Mean tumor weight Day 15 (g)	T/C ^b Day 15 (%)
0	0	21 ± 1 ^d	100	100	1.5 ± 0.3	
0	10.0	22 ± 1	100	100	1.5 ± 0.4	100
6.5	0	22 ± 1	100	100	1.4 ± 0.2	93
6.5	10.0	23 ± 2	100	100	1.4 ± 0.4	93
9.0	0	22 ± 2	100	0	0.7 ± 0.4	47
9.0	10.0	23 ± 2	100	0	0.8 ± 0.4	53
11.5	0	62 ± 23	100	0	0.42 ± 0.08	28
11.5	10.0	22 ± 2 ^e	100	0	0.38 ± 0.06	25
13.0	0	148 ± 85	100	0	0.12 ± 0.02	8
13.0	10.0	22 ± 3 ^e	100	0	0.12 ± 0.03	8
14.5	0	215 ± 34	0	0		7
14.5	10.0	93 ± 77 ^e	75	0	0.11 ± 0.02	7

^a Ebselen was given 1 h before cisplatin

^b T/C = mean tumor weight treated mice/mean tumor weight control mice.

^c Incidence of tumors was assessed by palpation

^d Mean ± SD

^e p<0.05 compared to the groups treated with cisplatin alone

The above experiments make it evident that ebselen can be a valuable prophylactic and/or therapeutic for the nephrotoxicity and/or neurotoxicity induced by cisplatin.

For prophylactic or pharmaceutical application in the case of side effects caused by medicinal treatment using cisplatin, Ebselen is administered orally or parenterally in a suitable dosage form at dose levels of 10 to 2000 mg per day, preferably 10 to 300 mg per day in one or several separate doses, preferably two to three doses per day.

Parenteral administration can take place according to the method described in DE-AS 38 26 892.

This present investigation applies to pharmaceutical preparations containing Ebselen as active ingredient. The preparations involved are such as are intended for enteral, i.e. oral or rectal, or parenteral administration in which the drug is present alone or in combination with the usual pharmaceutical excipients.

The pharmaceutical preparation of the drug preferably takes the form of individual doses, adjusted to the desired administration, e.g. tablets, sugarcoated tablets,

capsules, suppositories, granules, solutions, emulsions or suspensions. The usual dose of the substances is between 10 and 2000 mg per day, preferably between 10 and 300 mg per day and can be administered in the form of one dose or several doses, preferably two to three doses per day. The manufacture of the medicaments according to the invention is further illustrated in the following examples.

Example 1

Tablets

2-Phenyl-1,2-benzisoselenazol-3(2H)-one	30 mg
Lactose	150 mg
Crystalline cellulose	50 mg
Calcium carboxymethylcellulose	7 mg
Magnesium stearate	3 mg

The substances listed are mixed and pressed according to the usual methods, if required the pressings can be coated in the usual manner.

Example 2

Tablets

2-Phenyl-1,2-benzisoselenazol-3(2H)-one	50 mg
Microcrystalline cellulose	150 mg
Cutina ^R HR	15 mg
Hydroxypropylmethylcellulose phthalate	20 mg

25

Example 3**Caspules**

2-Phenyl-1,2-benzisoselenazol-3(2H)-one	30 mg
Lactose	102 mg
Crystalline cellulose	56 mg
Colloidal silicon dioxide	2 mg

The substances listed are mixed and granulated by the usual methods and filled into hard gelatine capsules.

Example 4**Capsules**

2-Phenyl-1,2-benzisoselenazol-3(2H)-one	50 mg
Talc	5 mg
Aerosil 200	10 mg

Claims

1. Use of 2-phenyl-1,2-benzisoselenazol-3(2H)-one for the manufacture of medicaments for the treatment and prophylaxis of the side-effects occurring on the medicinal administration of Cisplatin.
2. Use of a combination of Cisplatin with Ebselen for the manufacture of medicaments for the treatment of neoplastic diseases and prophylaxis of the side-effects occurring on the medicinal administration of Cisplatin, comprising of 10 mg to 100 mg Cisplatin and 10 mg to 2000 mg Ebselen.
3. Use according to claim 2, wherein Cisplatin and Ebselen are in the form of a medical kit, collection or package containing the two agents in separate but adjacent form.

4. Pharmaceutical composition for the treatment of the side-effects of Cisplatin comprising Ebselen and the usual pharmaceutical auxiliaries.
5. Pharmaceutical composition for the treatment of the side-effects of Cisplatin comprising a combination of Ebselen with Cisplatin in the form of a medical kit, collection or package containing the two agents in separate but adjacent form.
6. Method of treatment of the side-effects of Cisplatin by administering Ebselen prior, at the same time or later to the administration of Cisplatin.
7. Method of Claim 6.
where the administered dose of Ebselen is between 10 mg to 2000 mg per day in one or several doses orally or parenterally.
8. Method of treatment of neoplastic diseases by administering a combination of Cisplatin and Ebselen, said medicament comprising at 10 mg to 100 mg Cisplatin and 10 mg to 2000 mg Ebselen.

9. Pharmaceutical composition for the treatment of neoplastic diseases comprising of 10 mg to 100 mg Cisplatin and 10 mg to 2000 mg Ebselen and the usual pharmaceutical auxiliaries.
10. Pharmaceutical composition according to claim 9. mg to 2000 mg Ebselen.

Fig. 1a

• Control
 ○ Cisplatin 0.1 mM
 ▲ Cisplatin 0.2 mM
 △ Cisplatin 0.4 mM







Fig. 1b



2/3

- Cisplatin
 ● Cisplatin + Ebselen 5 μ M
 ■ Cisplatin + Ebselen 10 μ M
 ▲ Cisplatin + Ebselen 15 μ M

Fig. 2a

SUBSTITUTE SHEET

Fig. 3a





Fig. 3b




- ▲ Control
- Ebselen 10 μ M
- Ebselen 10 μ M + Cisplatin 0.4 mM
- Cisplatin 0.4 mM

SUBSTITUTE SHEET

INTERNATIONAL SEARCH REPORT

International Application No PCT/EP 91/01438

I. CLASSIFICATION OF SUBJECT MATTER (if several classification symbols apply, indicate all) ⁵		
According to International Patent Classification (IPC) or to both National Classification and IPC		
IPC5: A 61 K 31/41, 31/28//C 07 D 293/12		
II. FIELDS SEARCHED		
Minimum Documentation Searched ⁷		
Classification System	Classification Symbols	
IPC5	A 61 K; C 07 D	
Documentation Searched other than Minimum Documentation to the Extent that such Documents are Included in Fields Searched ⁸		
III. DOCUMENTS CONSIDERED TO BE RELEVANT⁹		
Category *	Citation of Document, ¹¹ with indication, where appropriate, of the relevant passages ¹²	Relevant to Claim No. ¹³
P,X	Dialog Information Services, File 155: Medline 66-91/Oct, accession no. 07485080, Medline accession no. 91004080, Baldew G.S. et al: "Selective reduction of cis-diamminedichloro- platinum(II) nephrotoxicity by ebselen", & Cancer Res Nov 1 1990, 50(21) p7031-7036, see the whole document	1-3
X	DE, A1, 3616923 (A. NATTERMANN & CIE GMBH) 26 November 1987, see the claims; page 2, lines 29-42; page 5, lines 5-23	1-3
Y	CANCER RESEARCH, vol. 49, June 1989, Glenn S. Baldew et al.: "Selenium-induced Protection against cis-Diamminedichloroplatinum(II) Nephrotoxicity in Mice and Rats ", see page 3020 - page 3023	1-3
<p>* Special categories of cited documents:¹⁰</p> <div style="display: flex; justify-content: space-between;"> <div style="width: 45%;"> <p>"A" document defining the general state of the art which is not considered to be of particular relevance</p> <p>"E" earlier document but published on or after the international filing date</p> <p>"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</p> <p>"O" document referring to an oral disclosure, use, exhibition or other means</p> <p>"P" document published prior to the international filing date but later than the priority date claimed</p> </div> <div style="width: 45%;"> <p>"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</p> <p>"X" document of particular relevance, the claimed invention cannot be considered novel or cannot be considered to involve an inventive step</p> <p>"Y" document of particular relevance, the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art</p> <p>"Z" document member of the same patent family</p> </div> </div>		
IV. CERTIFICATION		
Date of the Actual Completion of the International Search	Date of Mailing of this International Search Report	
30th September 1991	24. 10. 91	
International Searching Authority	Signature of Authorized Officer	
EUROPEAN PATENT OFFICE		
Mme Dagmar FRANK		

Form PCT/ISA/210 (second sheet) (January 1985)

III. DOCUMENTS CONSIDERED TO BE RELEVANT (CONTINUED FROM THE SECOND SHEET)		
Category *	Citation of Document, with indication, where appropriate, of the relevant passages	Relevant to Claim No
Y	DE, A1, 3638124 (A. NATTERMANN & CIE GMBH) 11 May 1988, see the claims --	1-3
A	CANCER RESEARCH, vol. 44, July 1984, Jean-Pierre Berry et al.: "Effect of Selenium in Combination with cis-Diamminedichloroplatinum(II) in the Treatment of Murine Fibrosarcoma ", see page 2864 - page 2868 --	1-3
A	DE, A, 3027073 (A. NATTERMANN & CIE GMBH) 18 February 1982, see the claim; page 2, lines 9-20 --	1-3
A	EP, A2, 0347927 (A. NATTERMANN & CIEGMBH) 27 December 1989, see the claim -- -----	1-3

**ANNEX TO THE INTERNATIONAL SEARCH REPORT
ON INTERNATIONAL PATENT APPLICATION NO. PCT/EP 91/01438**

SA 49663

This annex lists the patent family members relating to the patent documents cited in the above-mentioned international search report. The members are as contained in the European Patent Office EDP file on 30/08/91. The European Patent office is in no way liable for these particulars which are merely given for the purpose of information.

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
DE-A1- 3616923	26/11/87	EP-A- 0249735 JP-A- 62294613 US-A- 4757063	23/12/87 22/12/87 12/07/88
DE-A1- 3638124	11/05/88	JP-A- 63183528	28/07/88
DE-A- 3027073	18/02/82	AT-T- 4168 CA-A- 1177409 EP-A-B- 0044971 JP-C- 1582426 JP-B- 2006331 JP-A- 57056427 US-A- 4352799	15/08/83 06/11/84 03/02/82 11/10/90 08/02/90 05/04/82 05/10/82
EP-A2- 0347927	27/12/89	DE-A- 3821392	28/12/89

For more details about this annex : see Official Journal of the European patent Office, No. 12/82

EPO FORM P0479